Shu Yun, Wang Zhouyu, Shang Hongjuan, Le Wei, Lei Yan, Huang Longzhang, Tao Liming, Chen Jun, Li Jing
Department of Medical Oncology, Third People's Hospital of Jiujiang City, Jiujiang, China.
Department of Medical Affairs, Berry Oncology Corporation, Beijing, China.
Front Oncol. 2023 Apr 20;13:1169876. doi: 10.3389/fonc.2023.1169876. eCollection 2023.
C-ros oncogene 1 () fusion is a pathogenic driver gene in non-small cell lung cancer (NSCLC). Currently, clinical guidelines from the National Comprehensive Cancer Network (NCCN) have recommended molecular pathologic tests for patients with NSCLC, including the detection of the gene. Crizotinib is a small molecule tyrosine kinase inhibitor of anaplastic lymphoma kinase (), , and mesenchymal-epithelial transition (). In recent years, the efficacy of crizotinib in NSCLC patients with fusion has been reported. Here, a 77-year-old woman was diagnosed with stage IVA lung adenocarcinoma harboring a novel low-density lipoprotein receptor () fusion variant. This novel fusion was identified by targeted DNA next-generation sequencing (NGS) panel and then verified by RNA fusion panel based on amplicon sequencing. This patient benefited from subsequent crizotinib therapy and achieved progression-free survival of 15 months without significant toxic symptoms. Our case report recommended a promising targeted therapeutic option for patients with metastatic NSCLC with fusion and highlighted the importance of genetic testing for accurate treatment.
C-ros原癌基因1（ROS1）融合是非小细胞肺癌（NSCLC）中的一种致病驱动基因。目前，美国国立综合癌症网络（NCCN）的临床指南已建议对NSCLC患者进行分子病理检测，包括检测ROS1基因。克唑替尼是一种小分子酪氨酸激酶抑制剂，可抑制间变性淋巴瘤激酶（ALK）、ROS1和间质上皮转化因子（MET）。近年来，已有克唑替尼对ROS1融合的NSCLC患者疗效的报道。在此，一名77岁女性被诊断为IVA期肺腺癌，携带一种新的低密度脂蛋白受体（LDLR）融合变体。这种新的ROS1融合通过靶向DNA二代测序（NGS）面板鉴定，然后基于扩增子测序通过RNA融合面板进行验证。该患者从随后的克唑替尼治疗中获益，无明显毒性症状，实现了15个月的无进展生存期。我们的病例报告为具有ROS1融合的转移性NSCLC患者推荐了一种有前景的靶向治疗选择，并强调了基因检测对准确治疗的重要性。
